Bortezomib-containing regimen for primary treatment of early antibody-mediated cardiac allograft rejection: A case report

Progress in Transplantation

Volumn 25, Issue 2, 2015, Pages 147-152

  Gazdic, Tomas ^a   Svobodova, Eva ^a   Kubanek, Milos ^a   Kment, Martin ^a   Pagacova, Libuse ^a   Viklicky, Ondrej ^a   Malek, Ivan ^a   Kautzner, Josef ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIBODY; ANTINEOPLASTIC AGENT; BORONIC ACID DERIVATIVE; BORTEZOMIB; IMMUNOGLOBULIN; IMMUNOSUPPRESSIVE AGENT; METHYLPREDNISOLONE; MONOCLONAL ANTIBODY; PYRAZINE DERIVATIVE; RITUXIMAB;

ADULT; ADVERSE EFFECTS; ALLOGRAFT; CASE REPORT; DRUG COMBINATION; DRUG EFFECTS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOLOGY; PROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; ALLOGRAFTS; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; BORONIC ACIDS; DRUG THERAPY, COMBINATION; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; METHYLPREDNISOLONE; PROSPECTIVE STUDIES; PYRAZINES; TREATMENT OUTCOME;

EID: 84946114507     PISSN: 15269248     EISSN: 21646708     Source Type: Journal    
DOI: 10.7182/pit2015934     Document Type: Article

References (15)

1. Kobashigawa J, Crespo-Leiro MG, Ensminger, SM, et al. Report from a consensus conference on antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2011;30(3):252-269. doi:10.1016/j.healun.2010.11.003.
2. Walsh RC, Alloway RR, Girnita AL, Woodle ES. Proteasome inhibitor-based therapy for antibody-mediated rejection. Kidney Int. 2012;81(11):1067-1074. doi:10.1038/ki.2011.502.
3. Patel J, Everly M, Chang D, Kittleson M, Reed E, Kobashigawa J. Reduction of alloantibodies via proteosome inhibition in cardiac transplantation. J Heart Lung Transplant. 2011;30(12):1320-1326. doi:10.1016/j.healun.2011.08.009.
4. Eckman PM, Thorsgard M, Maurer D, Kim Y, Alloway RR, Woodle ES. Bortezomib for refractory antibody-mediated cardiac allograft rejection. Clin Transpl. 2009:475-478.
5. Morrow WR, Frazier EA, Mahle WT, et al. Rapid reduction in donor-specific anti-human leukocyte antigen antibodies and reversal of antibody-mediated rejection with bortezomib in pediatric heart transplant patients. Transplantation. 2012;93(3): 319-324. doi:10.1097/TP.0b013e31823f7eea.
6. Hodges AM, Lyster H, McDermott A, et al. Late antibodymediated rejection after heart transplantation following the development of de novo donor-specific human leukocyte antigen antibody. Transplantation. 2012;93(6):650-656. doi:10.1097/TP.0b013e318244f7b8.
7. Walsh RC, Everly JJ, Brailey P, et al. Proteasome inhibitorbased primary therapy for antibody-mediated renal allograft rejection. Transplantation. 2010;89(3):277-284. doi:10.1097/TP .0b013e3181c6ff8d.
8. Walsh RC, Brailey P, Girnita A, et al. Early and late acute antibody-mediated rejection differ immunologically and in response to proteasome inhibition. Transplantation. 2011;91(11):1218-1226.
9. Woodle ES, Light J, Franklin W, et al. Proteasome inhibitorbased primary therapy for antibody-mediated rejection in solid organ transplantation [abstract]. Am J Transplant. 2011; (suppl 4):159.
10. Stewart S, Winters GL, Fishbein MC, et al. Revision of the 1990 working formulation for the standardization of nomenclature in the diagnosis of heart rejection. J Heart Lung Transplant. 2005;24(11):1710-1720.
11. Berry GJ, Burke MM, Andersen C, et al. The 2013International Society for Heart and Lung Transplantation Working Formulation for the standardization of nomenclature in the pathologic diagnosis of antibody-mediated rejection in heart transplantation. J Heart Lung Transplant. 2013;32(12): 1147-1162. doi:10.1016/j.healun.2013.08.011.
12. Kfoury AG, Hammond ME, Snow GL, et al. Cardiovascular mortality among heart transplant recipients with asymptomatic antibody-mediated or stable mixed cellular and antibodymediated rejection. J Heart Lung Transplant. 2009;28(8):781-784. doi:10.1016/j.healun.2009.04.035.
13. Wu GW, Kobashigawa JA, Fishbein MC, et al. Asymptomatic antibody-mediated rejection after heart transplantation predicts poor outcomes. J Heart Lung Transplant. 2009;28(5): 417-422. doi:10.1016/j.healun.2009.01.015.
14. Chih S, Tinckam KJ, Ross HJ. A survey of current practice for antibody-mediated rejection in heart transplantation. Am J Transplant. 2013;13(4):1069-1074. doi:10.1111/ajt.12162.
15. Ravichandran AK, Schilling JD, Novak E, Pfeifer J, Ewald GA, Joseph SM. Rituximab is associated with improved survival in cardiac allograft patients with antibody-mediated rejection: a single center review. Clin Transplant. 2013;27(6): 961-967. doi:10.1111/ctr.12277.